000 02292 a2200709 4500
005 20250515064132.0
264 0 _c20070511
008 200705s 0 0 eng d
022 _a1526-632X
024 7 _a10.1212/01.wnl.0000259521.14704.a8
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBalcer, L J
245 0 0 _aNatalizumab reduces visual loss in patients with relapsing multiple sclerosis.
_h[electronic resource]
260 _bNeurology
_cApr 2007
300 _a1299-304 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650 0 4 _aAdolescent
650 0 4 _aAdult
650 0 4 _aAntibodies, Monoclonal
_xadministration & dosage
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aBrain
_xdrug effects
650 0 4 _aContrast Sensitivity
_xdrug effects
650 0 4 _aDouble-Blind Method
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aImmunosuppressive Agents
_xadministration & dosage
650 0 4 _aKaplan-Meier Estimate
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aMultiple Sclerosis, Relapsing-Remitting
_xcomplications
650 0 4 _aNatalizumab
650 0 4 _aNeurologic Examination
_xmethods
650 0 4 _aPlacebos
650 0 4 _aPredictive Value of Tests
650 0 4 _aTreatment Outcome
650 0 4 _aVision Tests
_xmethods
650 0 4 _aVision, Low
_xdrug therapy
650 0 4 _aVisual Acuity
_xdrug effects
650 0 4 _aVisual Pathways
_xdrug effects
700 1 _aGaletta, S L
700 1 _aCalabresi, P A
700 1 _aConfavreux, C
700 1 _aGiovannoni, G
700 1 _aHavrdova, E
700 1 _aHutchinson, M
700 1 _aKappos, L
700 1 _aLublin, F D
700 1 _aMiller, D H
700 1 _aO'Connor, P W
700 1 _aPhillips, J T
700 1 _aPolman, C H
700 1 _aRadue, E-W
700 1 _aRudick, R A
700 1 _aStuart, W H
700 1 _aWajgt, A
700 1 _aWeinstock-Guttman, B
700 1 _aWynn, D R
700 1 _aLynn, F
700 1 _aPanzara, M A
773 0 _tNeurology
_gvol. 68
_gno. 16
_gp. 1299-304
856 4 0 _uhttps://doi.org/10.1212/01.wnl.0000259521.14704.a8
_zAvailable from publisher's website
999 _c16988551
_d16988551